This study is for participants with symptoms of mast cell activation (SMAC). The primary purpose of this study is to learn about clonal mast cell diseases. Clonal mast cell diseases are hard to diagnose because symptoms are not specific, and they can overlap with other diseases. The tools currently used by doctors to look for clonal mast cell diseases in the blood may not identify all patients. This study is being done to develop an investigational blood test that looks for a change in a gene called KIT. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). Two types of blood tests will be compared against each other. Participants in this study can expect to be in this study for about 6 months.

This research study aims to better understand how the brain and body change during physical or occupational therapy after a neurologic injury or condition. Adults who are already receiving outpatient neurorehabilitation will be invited to participate while they complete their regular therapy sessions. During therapy, participants will wear a lightweight cap that measures brain activity and will be video recorded so researchers can analyze movement patterns using computer software. These recordings do not change therapy activities and are for research purposes only. The study does not involve new treatments, medications, or procedures beyond standard care. Information collected may help researchers understand why recovery differs between individuals and improve future rehabilitation approaches.

LiveWell mBC is a group-based skills training program for women with metastatic breast cancer (mBC). The program teaches skills from dialectical behavioral therapy, an evidence-based psychotherapy, that have been adapted specifically to help women live as well as possible, with metastatic breast cancer. LiveWell mBC involves meeting with a small group of women with mBC plus two skills trainers 9 times total via telemedicine. Meetings include orientation plus 8 sessions learning and practicing skills including mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness and they last 90 minutes each. We are interested in seeing whether the program can help women to balance their emotions and better manage distress (e.g., anxiety, sadness) and symptoms (e.g., fatigue, breathlessness, pain) that can be common when living with mBC.

Participants will be randomly assigned to one of two groups. They will have a 2 in 3 chance of being assigned to LiveWell mBC (experimental group) and a 1 in 3 chance of being assigned to Usual Care (control group). Women in the usual care group will continue to receive their standard oncology care. Participants in both groups will complete questionnaires four times total. Participants may be invited to participate in an exit interview about their experience. Participants will be compensated for completing questionnaires and the interview. For most people, participation will last approximately 4 months.

This study examines how parents and adolescents communicate about alcohol and marijuana during mid-to-late adolescence, a period marked by rising substance use risk. Although many parents want to reduce harm, they often receive unclear guidance, and what parents intend to convey may not align with what adolescents perceive. Building on prior work showing that alcohol-specific communication is multidimensional and meaningfully linked to youth drinking outcomes, this study surveys parent–adolescent dyads (ages 15–18) to assess the content, frequency, and perception of substance-related conversations. The study also extends prior research by directly comparing parent and youth reports to identify alignment and discrepancies in communication. In addition, it addresses a major gap by characterizing marijuana-specific parental communication, which remains understudied despite increasing adolescent use. Finally, the study tests whether parents' trauma histories, particularly trauma involving substance use, shape how and what parents communicate to their children about alcohol and marijuana.

The purpose of this study is to evaluate whether neuromuscular electrical stimulation (NMES) can help preserve muscle strength and muscle thickness in individuals living with amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that causes weakness and muscle loss over time. NMES is a therapy that uses small electrical impulses delivered through adhesive pads placed on the skin to stimulate muscles to contract.
Participants in this study will use a portable NMES device at home approximately three times per week for 12 weeks. One muscle group will receive active electrical stimulation while the same muscle group on the opposite side of the body will receive low-intensity stimulation that does not produce a visible muscle contraction. This allows researchers to compare the effects of stimulation within the same participant.
During the study, participants will attend periodic clinic visits where researchers will measure muscle strength, evaluate muscle thickness using ultrasound, and ask questions about symptoms such as fatigue, muscle cramps, and comfort with the device. A follow-up visit will occur four weeks after the stimulation period ends. The goal of this pilot study is to determine whether home-based NMES is safe, feasible, and acceptable for individuals with ALS and to gather preliminary information about whether it may help slow muscle decline.

The goal of the DDRCC Biorepository is to collect human samples and health information to store for future research. Samples to be collected are blood, tissue (gastrointestinal, liver, pancreas and/or lymph nodes), stool, and cheek swabs. Participants may be eligible to enroll if scheduled for a clinical visit or surgical procedure during which these samples could be collected.

The purpose of this study is to evaluate the efficacy and safety of ibuzatrelvir with and without remdesivir compared with remdesivir alone for the treatment of symptomatic COVID-19 in adult participants who are severely immunocompromised. This study is being done to learn how the study drug, called ibuzatrelvir, works in treating people with COVID-19 who have a severely compromised immune system. Ibuzatrelvir stops the virus that causes COVID-19 from multiplying in cells and spreading around the body. It may help people to get better and stay out of the hospital.

Feeding requires babies to coordinate sucking and swallowing, which depends on healthy brain development. Some newborns who experience brain injury or serious illness cannot safely practice feeding by mouth, which disrupts the development of these important brain circuits. As a result, many of these infants require a feeding tube placed in the stomach (called a G-tube) when they leave the hospital. Unfortunately, long-term feeding tube dependence is linked to poorer growth, delayed development, and breathing problems. Despite how common and serious these feeding difficulties are, there are currently no effective therapies for infants with the most severe swallowing problems. This study will test a non-invasive therapy called transcutaneous auricular vagus nerve stimulation (taVNS), which gently stimulates a nerve in the ear that connects to the brain. When paired with structured oral motor exercises, this approach may help strengthen the brain circuits needed for feeding. We will study 12 infants with severe feeding impairments to evaluate whether this therapy is safe, feasible, and shows early signs of benefit. This project will provide early evidence about whether a targeted brain-based therapy can improve feeding outcomes during a key window of early development.